FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Updates on Compounded Peptides New Drug Loft and VLS Pharmacy Report: FDA Set to Unban RFK Jr.'s Favorite Peptides When will the FDA reclassify BPC 157 to Category 1 Octagon AI